ARCT:NSD-Arcturus Therapeutics Holdings Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 54.45

Change

+0.67 (+1.25)%

Market Cap

USD 1.38B

Volume

0.91M

Avg Analyst Target

USD 51.38 (-5.65%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-10.60 (-2.41%)

USD175.37B 51.33 42.01
BNTX BioNTech SE

-13.47 (-3.61%)

USD90.37B 20.44 14.68
REGN Regeneron Pharmaceuticals Inc

-1.30 (-0.20%)

USD69.86B 11.79 9.07
VRTX Vertex Pharmaceuticals Incorpo..

+1.20 (+0.64%)

USD48.54B 24.67 16.64
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+17.90 (+4.65%)

USD35.84B N/A N/A
SGEN Seagen Inc

+2.64 (+1.72%)

USD27.94B 47.92 37.66
GMAB Genmab A/S

+0.84 (+1.99%)

USD27.66B 70.01 8.47
RPRX Royalty Pharma plc

+0.12 (+0.31%)

USD23.30B 31.08 12.35
ALNY Alnylam Pharmaceuticals Inc

+0.14 (+0.07%)

USD22.60B N/A N/A

ETFs Containing ARCT

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

+2.94 (+4.65%)

USD0.77B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

+1.88 (+1.44%)

USD7.36B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.59 %

+0.01 (+0.10%)

USD0.02B
MOON Direxion Moonshot Innovat.. 0.00 % 0.65 %

+0.32 (+0.94%)

N/A
UNIC:LSE Lyxor Index Fund - Lyxor .. 0.00 % 0.15 %

+0.16 (+0.93%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.52% 77% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.52% 77% C+ 73% C
Trailing 12 Months  
Capital Gain 16.12% 63% D 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.12% 63% D 38% F
Trailing 5 Years  
Capital Gain 71.71% 68% D+ 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.71% 68% D+ 59% F
Average Annual (5 Year Horizon)  
Capital Gain 120.78% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.78% 90% A- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 202.76% 12% F 7% F
Risk Adjusted Return 59.57% 85% B 75% C
Market Capitalization 1.38B 79% C+ 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.59 40% F 32% F
Price / Cash Flow Ratio -32.25 83% B 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -81.71% 33% F 21% F
Return on Invested Capital -31.62% 68% D+ 23% F
Return on Assets -34.11% 30% F 9% F
Debt to Equity Ratio 3.49% 67% D+ 81% B-
Technical Ratios  
Short Ratio 1.44 79% C+ 71% C-
Short Percent 10.97% 18% F 15% F
Beta 2.79 4% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector